Chart Industries Falls on EU Scrutiny of Baker Hughes Acquisition

Chart Industries, Inc. saw its share price decline by 1.8% in the June 11 session following a report detailing European Commission antitrust concerns regarding its pending acquisition of Baker Hughes' energy transition business. The $5.8 billion transaction is now under formal investigation by the EU's competition watchdog, which has set a provisional decision deadline of July 30, 2026. The news signals heightened regulatory risk for a deal initially announced in November 2025, which would consolidate significant capabilities in hydrogen, carbon capture, and liquefied natural gas equipment.

Context — [why this matters now]

The European Commission's scrutiny arrives during a period of heightened global antitrust enforcement, particularly for cross-border industrial mergers. In 2023, the EU blocked the proposed $17 billion merger between Schneider Electric and AVEVA on competition grounds in industrial software. The current investigation reflects a broader regulatory focus on the energy transition sector, where consolidation is seen as necessary for scaling technology but risks reducing supplier options for major infrastructure projects. The probe was triggered by the Commission's Phase I review, which identified potential competition issues requiring a deeper, Phase II investigation. This move extends the regulatory timeline and introduces uncertainty for merger arbitrage positions that had priced in a smoother approval process.

The macro backdrop includes elevated capital expenditure forecasts for clean energy infrastructure, with the International Energy Agency projecting annual investment to exceed $2 trillion by 2030. This growth attracts regulatory attention to ensure competitive markets. The catalyst for the EU's formal statement of objections is typically an inability to secure sufficient concessions from the merging parties during initial talks. Chart Industries and Baker Hughes now face a critical period to propose remedies, such as asset divestitures, to alleviate the Commission's concerns before the July deadline.

Data — [what the numbers show]

Chart Industries' stock closed at $148.71 on June 11, down from its previous close of $151.42. The 1.8% intraday drop erased approximately $290 million in market capitalization, bringing it to roughly $15.9 billion. The stock remains 12% below its 52-week high of $169.00, set in April 2026. The arbitrage spread—the gap between Chart's current price and the implied value of the cash-and-stock deal—widened to 4.5%, reflecting increased perceived risk of deal failure or renegotiation.

A comparison of key deal metrics shows the transaction's scale. The $5.8 billion purchase price represents a 9x estimated EBITDA multiple for the Baker Hughes unit. Chart Industries' pro-forma revenue would increase by approximately 35% to an estimated $8.5 billion annually. For context, the broader industrial gas and equipment sector, as tracked by the iShares U.S. Industrials ETF (IYJ), is up 5.2% year-to-date, while Chart's stock has declined 3.5% over the same period amid deal uncertainty.

Metric	Chart Industries Standalone	Pro-Forma Combined Entity
Market Cap	$15.9B	~$21.7B (est.)
LTM Revenue	~$6.3B	~$8.5B (est.)
Net Debt/EBITDA	3.2x	4.8x (est.)

Analysis — [what it means for markets / sectors / tickers]

The primary second-order effect is a potential repricing of merger arbitrage strategies across the industrial and energy technology sectors. Specialized funds that had established long Chart/short Baker Hughes pairs may reduce exposure, increasing volatility for both stocks. If the deal proceeds with mandated divestitures, smaller competitors like Cryofab Inc. or Gardner Cryogenics could benefit by acquiring spun-off assets. Conversely, a blocked deal would be a positive for direct competitors Air Products and Chemicals, Inc. and Linde plc, which would face one less consolidated rival in bidding for large LNG and hydrogen contracts. Their shares could see a 2-4% relief rally on a deal rejection.

A key limitation to a bearish read is the history of such Phase II investigations often concluding with approved remedies. Over 70% of EU Phase II cases from 2010-2025 ended with conditional clearance, not prohibition. The risk for Chart is that required divestitures could diminish the strategic value of the acquisition, particularly if it must sell coveted intellectual property or key manufacturing facilities. Positioning data shows institutional ownership of Chart Industries declined by 1.2 percentage points in Q1 2026, while short interest has crept up to 4.8% of the float. Flow analysis indicates options volume for July and August expiries has increased, with a skew toward puts, suggesting hedges against further downside.

Outlook — [what to watch next]

The definitive regulatory catalyst is the European Commission's binding decision, due by July 30, 2026. Prior to that, watch for any statement of remedies proposed by Chart Industries, likely filed by early July. The companies may also need to engage with other regulators, including the UK's Competition and Markets Authority, which could open its own review following the EU's lead. In the U.S., the Federal Trade Commission has not signaled a challenge but remains a latent risk.

Key price levels for Chart Industries stock include technical support at $145.50, its 200-day moving average, and resistance at $155.00, near its 50-day moving average. A break below $145 could signal a market expectation of significant deal concessions or collapse. For Baker Hughes, the relevant level is $32.50, the price at which its energy transition business was valued in the deal; a sustained move below this could indicate investor skepticism about the unit fetching a similar price elsewhere.

Frequently Asked Questions

What does the EU antitrust probe mean for Chart Industries shareholders?

Shareholders face increased uncertainty and potential dilution. The all-stock portion of the deal means Chart issues new shares to Baker Hughes shareholders. If the deal is blocked, the stock may rally on relief from avoided dilution and debt, but would forfeit expected revenue and cost synergies. If the deal is approved with conditions, the required divestitures could reduce the projected $200 million in annual cost savings, potentially impacting long-term earnings per share targets. The stock may trade in a range bound by deal probabilities until the July deadline.

How does this investigation compare to other major industrial mergers?